Brought to you by 
UMN Pharma licenses Protein Sciences' FluBlOk in Japan
12 Aug 2014
Executive Summary
Protein Sciences (develops protein vaccines, drugs, and diagnostics) licensed Japanese drug company UMN Pharma exclusive rights to its FluBlOk recombinant influenza vaccine in Japan.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UMN Pharma licenses Protein Sciences' FluBlOk in Japan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice